Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | PRCP | P42785 | 3/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18921431 | 0.87 | MAPK1 (0.33) | L3MBTL1HTR2C | |
| Trifluoroacetic Acid SCHEMBL30339088 | 0.82 | MEN1 (0.32) | — | |
| Trifluoroacetic Acid SCHEMBL30339598 | 0.77 | DPP4 (0.35) | L3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL18921382 | 0.74 | JAK2 (0.32) | L3MBTL1KDM1A | |
| Trifluoroacetic Acid SCHEMBL29966503 | 0.74 | JAK2 (0.32) | L3MBTL1KDM1A | |
| Trifluoroacetic Acid SCHEMBL30338680 | 0.73 | GABRP (0.36) | L3MBTL1KDM1A | |
| Trifluoroacetic Acid SCHEMBL29048254 | 0.73 | GPR6 (0.33) | KDM1A | |
| Trifluoroacetic Acid SCHEMBL30338798 | 0.72 | MGLL (0.40) | — | |
| Trifluoroacetic Acid SCHEMBL30338646 | 0.72 | CHRNB2 (0.33) | KDM1A | |
| Trifluoroacetic Acid SCHEMBL30339079 | 0.71 | CHRNB2 (0.33) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116547281-A | Isoxazolidines as RIPK1 inhibitors and uses thereof | 赛诺菲 | 2023-08-04 | — | — | CN | disclosed |
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | SANOFI (FR) | 2023-07-13 | — | — | US | disclosed |
| EP-4157835-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | SANOFI (FR) | 2023-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | RIPK1, RIPK4, RIPK2 | TRPA1 4116/4885L3MBTL1 4764/4885PRCP 3288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.